logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin us
 

News

boto imprimir
Date: 21/04/2017

IDIBELL researchers look for new drugs against melanoma


Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) participated in a study published recently in the by the journal Investigative Dermatology, entitled "AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK / ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact on melanoma prognosis and therapy. "

 

The authors describe how the overexpression of AURKA (Aurora kinase A, a protein involved in cell cycle control) is associated with a worse prognosis in patients with cutaneous melanoma. The expression of this protein depends on factors such as FOXM1 transcription factor and of ERK-MAPK activation signaling pathways, often due to the presence of BRAF or NRAS mutations. However, pharmacological inhibition or silencing AURKA FOXM1 and affects the proliferation and survival of melanoma cells, even those resistant to BRAF inhibitors. The excellent results in pre-clinical studies suggest that the use of inhibitors and AURKA FOXM1 can benefit melanoma patients resistant to therapy anti-BRAF and / or NRAS mutations carriers so far about treatments orphans .

 

Several researchers linked to IDIBEL participated in this study: Drs JR Marcoval J Ferreres and the Department of Dermatology at the University Hospital of Bellvitge; Drs MA Pujana, JM Piulats, L Palomero and F Mateo from ICO-IDIBELL and E. Cabré and A Vinyals, led by Dr. Fabra at IDIBELL's Molecular Oncology lab.

 

The work has been funded with the support of "TV3 Marathon Foundation"; the "Spanish Association Against Cancer (AECC)"; the "AGAUR"; "RTICC"; "ISCIII" and "Fondos FEDER."





foto IDIBELL research team
IDIBELL research team

Share/Bookmark
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell